Alyeska Investment Group
BCRX icon

Alyeska Investment Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Alyeska Investment Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-450,000
Closed -$2.21M – 451
2017
Q4 		$2.21M Hold
450,000
– – 0.02% 328
2017
Q3 		$2.36M Buy
+450,000
New +$2.3M 0.02% 347

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Alyeska Investment Group's BCRX Position: Q1 2018 in Review

Alyeska Investment Group sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2018, closing a stake of 450,000 shares — an estimated $2.21M sold.

Alyeska Investment Group first reported a position in BCRX in Q3 2017 and held it in 2 quarters. The position peaked at $2.36M in Q3 2017. 103 funds tracked by Wall St. Rank hold BCRX as of Q1 2018.

  • Alyeska Investment Group reported no remaining BioCryst Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 450,000 BioCryst Pharmaceuticals shares in Q1 2018, an estimated $2.21M.
  • Alyeska Investment Group first reported a position in BioCryst Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Alyeska Investment Group's BioCryst Pharmaceuticals position peaked at $2.36M in Q3 2017.
  • 103 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2018.

Based on Alyeska Investment Group's 13F filing for Q1 2018, filed 15 May 2018.